NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Institute of Medicine (US) Forum on Emerging Infections; Knobler SL, Lemon SM, Najafi M, et al., editors. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Washington (DC): National Academies Press (US); 2003.

Cover of The Resistance Phenomenon in Microbes and Infectious Disease Vectors

The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary.

Show details

Appendix APublic Health Consequences of Use of Antimicrobial Agents in Agriculture

, D.V.M., M.P.H., , M.P.H., , M.P.H., and , D.V.M., Ph.D.

Foodborne and Diarrheal Diseases Branch, Division of Bacterial and Mycotic Diseases, Centers for Disease Control and Prevention, Atlanta, GA

Antimicrobial agents have been used in agriculture, including livestock and poultry, since the early 1950s to treat infections and improve growth and feed efficiency. The actual amount of antimicrobial agents used in agriculture is unknown; however, a substantial portion given to food animals is for subtherapeutic use (i.e., use in the absence of disease) for growth promotion, a practice that is becoming increasingly controversial. The agricultural use of antimicrobial agents that have a human analog increases the likelihood that human bacterial pathogens that have food animal reservoirs will develop cross-resistance to drugs approved for use in human medicine. The World Health Organization (WHO), following a series of consultations in 1997, 1999, and 2000, has recommended that the use of antimicrobial growth promoters that belong to an antimicrobial class used in humans be terminated in the absence of risk-based evaluations (WHO, 1997, 1999, 2000).

Several European countries have already taken steps toward this goal. In 1998, the European Union banned four growth promoters (tylosin, spiramycin, bacitracin, and virginiamycin) because of their structural relatedness to antimicrobial agents used in human medicine (European Commission, 1998). In that same year, chicken farmers and beef producers in Denmark voluntarily stopped using antimicrobial agents as growth promoters; swine farmers followed suit in 1999. This ban has reduced the total volume of antibiotics used in food animals in Denmark by 60 percent (from 206 to 81 tons) (DANMAP, 2000; Sorensen et al, 2002). Studies to investigate the influence of the ban have shown no negative consequence for farmers' profits or animal health in broiler chickens (Emborg et al., 2001). Similar conclusions were reported in fattening pigs, although diarrhea in weaned piglets has required other interventions, such as improved feeding and weaning procedures (Sorensen et al., 2002). In Sweden, all antibiotics were banned as growth promoters in 1986, decreasing their total antibiotic usage by 55 percent and demonstrating their ability to achieve competitive production results in the absence of growth promoters (Wierup, 1998; Greko, 1999). The effects of discontinuation of growth promoters in these countries have been a decrease in antibiotic resistance in animals, food products, and humans (Bager et al., 1999; Klare et al., 1999; Pantosti et al., 1999; DANMAP, 2000; van den Bogaard et al, 2000a; Aarestrup et al, 2001).

Clinicians should be aware that antimicrobial resistance is increasing in foodborne pathogens such as Salmonella and Campylobacter and that patients who are taking antimicrobial agents for any reason are at increased risk for acquiring antimicrobial-resistant foodborne infections. The increasing prevalence of antimicrobial resistance among these pathogens increases the potential for treatment failures and other adverse outcomes, including death. Appropriate use of antimicrobial agents in humans and food animals is necessary to maintain their effectiveness and reduce the potential for spread of resistant organisms. While therapeutic usage of antimicrobial agents in food animals is important to promote animal health and provide an affordable supply of meat, milk, and eggs, it is vital that the long-term effectiveness of antimicrobial agents used in human medicine be preserved. This report presents current surveillance information on the frequency of resistant foodborne infections in the United States, reviews scientific evidence linking antimicrobial agent usage in agriculture to resistant foodborne infections in humans, and makes recommendations for measures to protect public health.

Antimicrobial Use in Food Animals

At least 17 classes of antimicrobial agents are approved for growth promotion and feed efficiency in the United States, including tetracyclines, penicillins, macrolides, lincomycin (analog of clindamycin), and virginiamycin (analog of quinupristin/dalfopristin). To understand the human health consequences of the agricultural use of antimicrobial agents, it is important to evaluate the quantity of antimicrobials used in U.S. agriculture. Unfortunately, no reporting system exists for the quantity of antimicrobials used in food animals in the United States. The Animal Health Institute (AHI), which represents 80 percent of the companies that produce antimicrobials for animals in the United States, has estimated that their member companies produced 18 million pounds of antimicrobials for use in food animals in the United States in 1999 (AHI, 2000). An alternative estimate was provided by the Union of Concerned Scientists (UCS) in 2001 which calculated that 89 percent of the 35 million pounds of antimicrobial agents used annually in the United States are given to animals. Of the amount used in agriculture, 28 million pounds (93 percent) are used in the absence of disease (Mellon et al., 2001). Though more precise data on the quantity of antimicrobial agents used in food animals is needed, these initial estimates provide some perspective on the quantity.

As in human medicine, the use of antimicrobial agents in agriculture creates a selective pressure for the emergence and dissemination of antimicrobial-resistant bacteria including animal pathogens, human pathogens which have food animal reservoirs, and other bacteria which are present in food animals (Cohen and Tauxe, 1986; Levy, 1997; van den Bogaard and Stobberingh, 1999). These resistant bacteria may be transferred to humans either through the food supply or by direct contact with animals (Oosterom, 1991; Levy, 1997; Khachatourians, 1998; Witte, 1998). The transfer of resistant bacteria from food-producing animals to humans is most evident in human bacterial pathogens which have food animal sources, such as Campylobacter, which has a reservoir in chickens and turkeys (Tauxe, 1992; USDA, 1996; Altekruse et al, 1999), and Salmonella, which has reservoirs in cattle, chickens, pigs, and turkeys (Meng and Doyle, 1998; Angulo et al., 2000). To monitor antimicrobial resistance in foodborne enteric pathogens, the National Antimicrobial Resistance Monitoring System (NARMS) for Enteric Bacteria was launched in 1996.

NARMS is a collaboration among the Centers for Disease Control and Prevention (CDC), the Center for Veterinary Medicine at the Food and Drug Administration (FDA), the United States Department of Agriculture (USDA), and state and local health departments. In addition to NARMS, the Foodborne Diseases Active Surveillance Network (FoodNet) conducts population-based studies to estimate the burden and sources of specific foodborne diseases in nine states.


NARMS has been used to monitor the prevalence of fluoroquinolone-resistant Campylobacter in the United States since 1997. The emergence of fluoroquinolone resistance among Campylobacter is an example of antimicrobial resistance resulting from the use of antimicrobial agents in food animals and the subsequent transfer via the food supply of resistant bacteria to humans. Fluoroquinolones were approved for human medicine in 1986. A national prospective study of reported Campylobacter cases between 1989–1990 found no Campylobacter isolates to be resistant to fluoroquinolones (CDC, 2000). The first fluoroquinolones approved for use in food animals in the United States were sarofloxacin in 1995 and enrofloxacin in 1996. These fluoroquinolones were approved for the treatment of respiratory disease in chickens and turkeys.

A study conducted in Minnesota reported that resistance of human Campylobacter jejuni infections to quinolones increased from 1 percent in 1992 to 10 percent in 1998. Resistant infections that were domestically acquired increased significantly from 1996 through 1998, a finding that was temporally associated with the licensure of fluoroquinolones for use in poultry in 1995. Molecular subtyping of human isolates and domestic chicken products from retail stores showed a significant association between resistant Campylobacter jejuni strains from chickens and domestically acquired infections in residents (Smith et al., 1999). Testing of 1997 NARMS Campylobacter jejuni isolates found fluoroquinolone resistance among 13 percent of the isolates; this figure has remained high at 14 percent of isolates in 2000 (CDC, 2000).

In a case-control study of fluoroquinolone-resistant Campylobacter infections conducted in the FoodNet sites, 58 percent of resistant infections were acquired domestically (Kassenborg et al., unpublished data). When domestically acquired fluoroquinolone-resistant Campylobacter cases were compared with well controls, cases were 10 times more likely to have eaten poultry cooked at a commercial establishment. Since chicken is not imported into the United States, this observation supports the conclusion that poultry is the dominant source of domestically acquired fluoroquinolone-resistant Campylobacter infections in the United States. In a recent risk assessment, FDA concluded that the use of fluoroquinolones in chickens in the United States has compromised the treatment with fluoroquinolones of almost 10,000 people a year; meaning that each year, thousands of people with Campylobacter infections seek medical care and are treated with fluoroquinolones, but their infection is already fluoroquinolone-resistant (FDA, 2000).


In addition to fluoroquinolone-resistant Campylobacter, there is also the potential for an emergence of domestically acquired fluoroquinolone-resistant Salmonella in the United States. Fluoroquinolones are the most commonly used antimicrobial for the treatment of invasive Salmonella infections in adults (Angulo et al., 2000). In 2000, 1.4 percent of Salmonella isolates collected by NARMS had a decreased susceptibility to fluoroquinolones (MIC ≥ 0.25 μg/ml), an increase from 0.4 percent in 1996 (CDC, 2000). This decreasing susceptibility to fluoroquinolones among Salmonella infections is of immediate concern as isolates with a MIC ≥ 0.25 μg/ml typically only require a single additional point mutation to become resistant (MIC ≥ 4 μg/ml), and therefore represent a potential reservoir for the emergence of resistant Salmonella should such isolates be exposed to continued selective pressure (Nakamura et al., 1993). Furthermore, patients infected with Salmonella strains with a decreased susceptibility to fluoroquinolones may respond poorly to treatment with fluoroquinolones and have been associated with apparent treatment failures (Molbak et al., 1999; Angulo et al, 2000).

Third-generation cephalosporins, such as ceftriaxone, are commonly used for treatment of invasive Salmonella infections in children because of their pharmacodynamic properties and low prevalence of resistance to these agents. There is therefore concern about the potential emergence of ceftriaxone-resistant Salmonella. The first reported case of domestically acquired ceftriaxone-resistant Salmonella was in a 12-year-old child in Nebraska (Fey et al., 2000). Investigation by public health officials revealed that the child lived on a farm and his father was a veterinarian. Before the child's illness, the father was treating several cattle herds for outbreaks due to culture-confirmed Salmonella infection.

Although no information was available regarding the use of antimicrobial agents among the infected herds, a third-generation cephalosporin, ceftiofur, is widely used in cattle. Ceftriaxone-susceptible and ceftriaxone-resistant Salmonella were isolated from ill cattle treated by the veterinarian. Both ceftriaxone-resistant and ceftriaxone-susceptible cattle isolates and the ceftriaxone-resistant isolate from the child had similar genetic structures as determined by pulsed-field gel electrophoresis (PFGE). These similar molecular “fingerprints” and their temporal isolation suggest that ceftriaxone resistance emerged in the cattle herds, probably following use of ceftiofur or other antibiotics that would have selected for and maintained the ceftriaxone-resistant determinant within the intestinal flora of the involved herds.

The Nebraska child's ceftriaxone-resistant infection was not an isolated event. The percentage of non-Typhi Salmonella isolates in NARMS resistant to ceftriaxone increased 13-fold from 0.1 percent in 1996 to 1.3 percent in 2000 (CDC, 2000). When patients from whom isolates were received in 1996–1998 were interviewed, few reported international travel, suggesting that most infections were domestically acquired (Fey et al., 2000). Furthermore, ceftriaxone resistance in most domestically acquired infections is due to a unique AmpC-type resistance gene (CMY-2), which resides on a plasmid. The finding of a similar molecular mechanism of resistance among different Salmonella strains supports horizontal dissemination of a resistance determinant (Dunne et al., 2000). A 1999 study at the University of Iowa found multi-drug-resistant, cephalosporin-resistant bovine, porcine, and human Salmonella isolates from the same geographic region. All human and animal resistant isolates encoded a CMY-2 AmpC-like gene (Winokur et al., 2000).

The emergence of multi-drug-resistant Salmonella typhimurium definitive type 104 (DT104) in the United States and the United Kingdom, which is resistant to ampicillin, chloramphenicol, streptomycin, sulfonamides, and tetracycline (ACSSuT), is an example of how a highly resistant clone of Salmonella has the ability to effectively spread among animals and then to humans. Described by Glynn et al. (1998), the emergence of S. typhimurium DT104 in the United States can be traced back to as early as 1985 (Glynn et al., 1998). The prevalence of Typhimurium isolates with the five-drug pattern of resistance increased from 0.6 percent in 1979–1980 to 34 percent in 1996 (Glynn et al., 1998). Among Typhimurium isolates submitted to NARMS, the prevalence of the ACSSuT resistance pattern was 28 percent in both 1999 and 2000 (CDC, 2000).

The highest frequency of ceftriaxone-resistant Salmonella among NARMS isolates is emerging in multi-drug-resistant (MDR) Salmonella Newport, which is defined as resistance to at least ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, and tetracycline. Of all MDR Salmonella Newport isolates submitted to NARMS in 2000, a remarkable 50 percent are resistant to ceftriaxone (CDC, 2000).

Commensal Bacteria

Pathogenic bacteria, such as Campylobacter and Salmonella, are not the only concern when considering antimicrobial resistance in bacteria with food animal reservoirs. Commensal bacteria, which are naturally occurring host flora, constitute an enormous potential reservoir of resistance genes for pathogenic bacteria. The prevalence of antibiotic resistance in the commensal bacteria of humans and animals is considered to be a good indicator of the selective pressure of antibiotic usage and reflects the potential for resistance in future infections (Hummel et al., 1986; Lester et al., 1990; Murray, 1992; van den Bogaard et al, 2000b).

Most resistant bacteria have mobile genetic elements such as R-plasmids and transposons. As the reservoir of resistant commensal bacteria increases, the plasmid reservoir becomes larger and enables more frequent transfer of resistance to pathogenic bacteria including Salmonella and Shigella. Escherichia coli, which is the predominant isolate of aerobic fecal flora in humans and most animals, has demonstrated its ability to transfer resistance genes to other species, including pathogenic bacteria (Chaslus-Dancla et al., 1986; Hummel et al., 1986; Tauxe et al., 1989; Shoemaker et al, 1992; Nikolich et al, 1994; Berkowitz and Mechock, 1995; Winokur et al., 2001). Recent studies have shown an emerging resistance in E. coli to fluoroquinolones and third-generation cephalosporins. A study by Garau et al. (1999), demonstrated an increase in quinolone-resistant E. coli infections in Spain from 9 percent to 17 percent over the course of five years. This study also showed a high prevalence of quinolone-resistant E. coli in healthy children and adults (26 percent and 24 percent, respectively) which could not be explained by previous use of quinolones.

Animal testing from slaughterhouses in the area found a high rate of quinolone-resistant E. coli in swine and chickens (45 percent and 90 percent, respectively) (Garau et al., 1999). Winokur et al. (2001) found 16 percent of clinical E. coli isolates from cattle and swine and 1 percent of clinical human E. coli isolates collected in Iowa to be resistant to extended spectrum cephalosporins. This study also identified identical CMY-2 genes in resistant isolates from both humans and animals, suggesting transfer of the resistance gene between food animals and humans.

Another example of potential animal-to-human transfer of resistant commensal bacteria is quinupristin/dalfopristin-resistant Enterococcus faecium. Quinupristin/dalfopristin (Synercid®) was approved for use in humans in 1999 for treatment of vancomycin-resistant E. faecium infections. However, virginiamycin, an analog of quinupristin/dalfopristin that is cross-resistant, has been used as a growth promoter in food animals in the United States since 1974 (Rende-Fournier et al., 1993; National Research Council, 1999). A study conducted by CDC in 1998–1999, before the approval of Synercid® use in humans, found quinupristin/dalfopristin-resistant E. faecium on 58 percent of chickens purchased in grocery stores from four different states. Additionally, quinupristin/dalfopristin-resistant E. faecium was found in 1 percent of the stools from non-hospitalized people who submitted a stool specimen to clinical laboratories (McDonald et al., 2001). Similar data in Europe led the European Union to ban the subtherapeutic use of virginiamycin in food animals in 1998 (Wegener et al., 1999). These findings suggest virginiamycin use in chickens has created a large reservoir of quinupristin/dalfopristin-resistant E. faecium to which humans are commonly exposed. The use of quinupristin/dalfopristin in humans for the treatment of vancomycin-resistant E. faecium and other serious infections may contribute additional selective pressure leading to an increased prevalence of quinupristin/dalfopristin resistance in humans.

Clinical Implications

Two human health consequences of increasing antimicrobial resistance in foodborne bacteria are an increase in foodborne illnesses and an increase in number of treatment failures. Increased human infections by resistant foodborne pathogens occur as the prevalence of resistance increases and as humans are exposed to antimicrobial agents. Taking an antimicrobial may lower the infectious dose for Salmonella and potentially other foodborne bacteria, if the pathogen is resistant to that antimicrobial (Ryan et al., 1985). Analyses of antimicrobial-resistant Salmonella outbreaks have demonstrated that previous exposure to antimicrobials can result in a larger number of cases than would have occurred if the outbreak had been caused by a sensitive strain (Cohen and Tauxe, 1986).

Bohnhoff et al., showed in the early 1960s that mice with an “undisturbed” normal intestinal flora have a Salmonella infectious dose of about 106 organisms (Bohnhoff aand Miller, 1962). When they “disturbed” the normal flora by administering streptomycin, the infectious dose for streptomycin-resistant Salmonella decreased to only 10 organisms. In Salmonella outbreaks, it has been observed that preceding, unrelated treatment with an antimicrobial can predispose humans to infection with resistant (Holmberg et al., 1984; Ryan et al., 1987; Spika et al., 1987) or susceptible Salmonella (Pavia et al., 1990). Similarly, in studies of sporadic salmonellosis, preceding treatment with an antimicrobial was a risk factor for a resistant infection, compared to susceptible infections (Riley et al., 1984; MacDonald et al., 1987; Lee et al., 1994). Physicians should be aware that as foodborne pathogens become increasingly resistant, treating patients with antimicrobials, regardless of the reason, increases the risk for that patient to develop a subsequent infection caused by resistant foodborne bacteria. The public health impact of this potentiation effect is more cases of illness and larger outbreaks.

In addition to causing more human illnesses, increasing antimicrobial resistance in foodborne pathogens may result in treatment failures if the foodborne pathogen is resistant to an antimicrobial used for treatment. As previously described, resistance is emerging to antimicrobials commonly used for treatment of serious Salmonella infections, that is, fluoroquinolones in adults and extended-spectrum cephalosporins in children. An example of probable treatment failures was recently described by researchers in Denmark, where a multi-drug-resistant S. typhimurium DT104 outbreak attributed to contaminated pork was traced back to a swine herd (Molbak et al., 1999). The Salmonella isolates from humans and pork samples had decreased susceptibility to fluoroquinolones, and two patients who were treated with fluoroquinolones died. An official review of these deaths concluded that decreased susceptibility to fluoroquinolones was a contributing factor.


Given that there is an increasing prevalence of antimicrobial resistance and that this resistance has clinical implications, there is a need for mitigation efforts. Such actions will require collaborative efforts by several partners, including the farming, veterinary, medical, and public health communities. Enhanced surveillance is essential for evaluating and directing these efforts. There is a particular need to establish surveillance of antimicrobial usage in animals.

In the United States, collaborative federal actions to address antimicrobial resistance in agriculture are outlined in the Public Health Action Plan to Combat Antimicrobial Resistance, released in 2001 by an interagency task force (U.S. Government, 2001). Action items in this plan include improved surveillance of antimicrobial drug use and resistance, research and education, and, as a top priority item, refining and implementing the FDA's Framework Document. This Framework Document proposes a modified approval process for antimicrobials used in animals (FDA, 1999). It intends to ensure the human safety of antimicrobials used in animals by prioritizing these drugs according to their importance in human medicine. Additionally, it proposes to establish required mitigation actions with increasing resistance and to account for resistance developing from specific animal uses. Education of veterinarians regarding appropriate use of antibiotics has been promoted by the American Veterinary Medical Association (AVMA) with published guidelines for the therapeutic use of antibiotics (AVMA, 1998).

The widespread use of antimicrobial agents in food animals is associated with increasing antimicrobial resistance in foodborne pathogens, which subsequently may be transferred to humans. The transfer of these resistant bacteria or the genetic determinants for resistance causes adverse health consequences in humans by increasing the number of foodborne illnesses and increasing the potential for treatment failures. To address this public health problem, overuse and misuse of antimicrobial agents in food animals and humans must be reduced. This will be accomplished by adherence to guidelines for therapeutic use of antimicrobial agents in food animals, and the discontinuation of use of antimicrobial agents with a human analog as growth promoters unless risk assessments have indicated their safety for public health. Several European countries have already demonstrated the feasibility of such measures and the effectiveness of these interventions to combat antimicrobial resistance and reduce public health risks.


  • Aarestrup FM, Seyfarth AM, Emborg HD, Pedersen K, Hendriksen RS, Bager F. Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark. Antimicrobial Agents and Chemotherapy. 2001;45:2054–2059. [PMC free article: PMC90599] [PubMed: 11408222]
  • AHI (Animal Health Institute). Survey indicates most antibiotics used in animals are used for treating and preventing disease. 2000. Press release. February 14. [Online]. Available: http://www​​/press%20release​/2000/feb/antibiotic​%20usage%20data.htm.
  • Altekruse S, Stern N, Fields P, Swerdlow D. Campylobacter jejuni—an emerging foodborne pathogen. Emerging Infectious Diseases. 1999;5:28–35. [PMC free article: PMC2627687] [PubMed: 10081669]
  • Angulo FJ, Johnson KR, Tauxe RV, Cohen ML. Origins and consequences of antimicrobial-resistant nontyphoidal Salmonella: implications for the use of fluoroquinolones in food animals. Microbial Drug Resistance. 2000;6:77–83. [PubMed: 10868811]
  • AVMA (American Veterinary Medical Association). Judicious Therapeutic Use of Antimicrobials. 1998. [Online]. Available: http://www​​/jtua/jtua98.asp. [PubMed: 9743708]
  • Bager F, Aarestrup FM, Madsen M, Wegener HC. Glycopeptide resistance in Enterococcus faecium from broilers and pigs following discontinued use of avoparcin. Microbial Drug Resistance Mechanisms, Epidemiology and Disease. 1999;5:53–56. [PubMed: 10332722]
  • Berkowitz FE, Mechock B. Third generation cephalosporin-resistant gram-negative bacilli in the feces of hospitalized children. Pediatric Infectious Disease Journal. 1995;14:97–100. [PubMed: 7746715]
  • Bohnhoff M, Miller CP. Enhanced susceptibility to Salmonella infection in streptomycin-treated mice. Journal of Infectious Diseases. 1962;111:117–127. [PubMed: 13968487]
  • CDC (Centers for Disease Control and Prevention). NARMS 2000 Annual Report. 2000. [Online]. Available: http://www​
  • Chaslus-Dancla E, Martel JL, Carlier C, Lafont JP, Courvalin P. Emergence of aminoglycoside 3-N-acetyltransferase IV in Escherichia coli and Salmonella typhimurium isolated from animals. Antimicrobial Agents and Chemotherapy. 1986;29:239–243. [PMC free article: PMC176384] [PubMed: 3521474]
  • Cohen ML, Tauxe RV. Drug-resistant Salmonella in the United States: an epidemiological perspective. Science. 1986;234:964–969. [PubMed: 3535069]
  • DANMAP. Consumption of Antimicrobial Agents and Resistance to Antimicrobial Agents in Bacteria from Food Animals, Food and Humans in Denmark. 2000. Report from Statens Serum Institut, Danish Veterinary and Food Administration, Danish Medicines Agency and Danish Veterinary Institute. [Online]. Available: http://www​​/dk/Publikationer/Danmap/Danmap%202000​.pdf.
  • Dunne EF, Fey PD, Kludt P, Reporter R, Mostashari F, Shillam P, Wicklund J, Miller C, Holland B, Stamey K, Barrett TJ, Rasheed JK, Tenover FC, Ribot EM, Angulo FJ. Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with ampC beta-lactamase. Journal of the American Medical Association. 2000;284:3151–3156. [PubMed: 11135779]
  • Emborg H, Ersboll AK, Heuer OE, Wegener HC. The effect of discontinuing the use of antimicrobial growth promoters on the productivity in the Danish broiler production. Preventive Veterinary Medicine. 2001;50:53–70. [PubMed: 11448495]
  • European Commission. Commission regulation of amending council directive 70/524/EEC concerning additives in feeding stuffs as regards withdrawal of the authorization of certain antibiotics. European Commission; Brussels: 1998. Document No.: VI/7767/98.
  • FDA (Food and Drug Administration). A Proposed Framework for Evaluating and Assuring the Human Safety of the Microbial Effects of Antimicrobial New Animal Drugs Intended for Use in Food-Producing Animals. 1999. [Online]. Available: http://www​​/index/vmac/antimi18.html#statement.
  • FDA. Human Health Impact Fluoroquinolone-Resistant Campylobacter Attributed to the Consumption of Chicken. 2000. [Online]. Available: http://www​​/antimicrobial/Risk_asses.pdf.
  • Fey PD, Safranek TJ, Rupp ME, Dunne EF, Ribot E, Iwen PC, Bradford PA, Angulo FJ, Hinrichs SH. Ceftriaxone-resistant Salmonella infection acquired by a child from cattle. New England Journal of Medicine. 2000;342:1242–1249. [PubMed: 10781620]
  • Garau J, Xercavins M, Rodriguez-Carballeira M, Gomez-Vera JR, Coll I, Vidal D, Llovet T, Ruiz-Bremon A. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrobial Agents and Chemotherapy. 1999;43:2736–2741. [PMC free article: PMC89552] [PubMed: 10543756]
  • Glynn MK, Bopp C, Dewitt W, Dabney P, Mokhtar M, Angulo FJ. Emergence of multidrug-resistant Salmonella enterica serotype typhimurium DT104 infections in the United States. New England Journal of Medicine. 1998;338:1333–1338. [PubMed: 9571252]
  • Greko C. Antibiotics as growth promoters. Acta Veterinaria Scandinavica. 1999 Suppl 92:87–100. [PubMed: 10783721]
  • Holmberg SD, Osterholm MT, Senger KA, Cohen ML. Drug-resistant Salmonella from animals fed antimicrobials. New England Journal of Medicine. 1984;311:617–622. [PubMed: 6382001]
  • Hummel R, Tschape H, Witte W. Spread of plasmid-mediated nourseothricin resistance due to antibiotic use in animal husbandry. Journal of Basic Microbiology. 1986;26:461–466. [PubMed: 3033194]
  • Khachatourians GG. Agricultural use of antibiotics and the evolution and transfer of antibiotic-resistant bacteria. Canadian Medical Association Journal. 1998;159:1129–1136. [PMC free article: PMC1229782] [PubMed: 9835883]
  • Klare I, Badstubner D, Konstabel C, Bohme G, Claus H, Witte W. Decreased incidence of VanA-type vancomycin-resistant enterococci isolated from poultry meat and fecal samples of humans in the community after discontinuation of avoparcin usage in animal husbandry. Microbial Drug Resistance. 1999;5:45–52. [PubMed: 10332721]
  • Lee LA, Puhr ND, Maloney EK, Bean NH, Tauxe RV. Increase in antimicrobial-resistant Salmonella infections in the United States, 1989–1990. Journal of Infectious Diseases. 1994;170:128–134. [PubMed: 8014487]
  • Lester SC, del Pilar Pla M, Wang F, Perez Schael I, Jiang H, O'Brien TF. The carriage of Escherichia coli resistant to antimicrobial agents by healthy children in Boston, in Caracas, Venezuela, and in Qin Pu, China. New England Journal of Medicine. 1990;323:285–289. [PubMed: 2195344]
  • Levy SB. Antibiotic resistance: an ecological imbalance. In: Levy SB, Goode J, Chadwick DJ, editors. Antibiotic Resistance: Origins, Evolution, Selection, and Spread. New York: John Wiley & Sons; 1997. pp. 1–9.
  • MacDonald KL, Cohen ML, Hargrett-Bean NT, Wells JG, Puhr ND, Collin SF, Blake PA. Changes in antimicrobial resistance of Salmonella isolated from humans in the United States. Journal of the American Medical Association. 1987;258:1496–1499. [PubMed: 3625949]
  • McDonald LC, Rossiter S, Mackinson C, Wang YY, Johnson S, Sullivan M, Sokolow R, DeBess E, Gilbert L, Benson JA, Hill B, Angulo FJ. Quinupristin-dalfopristin-resistant Enterococcus faecium on chicken and in human stool specimens. New England Journal of Medicine. 2001;345:1155–1160. [PubMed: 11642231]
  • Mellon M, Benbrook C, Benbrook K. Hogging It: Estimates of Antimicrobial Abuse in Livestock. Cambridge: Union of Concerned Scientists Publications; 2001.
  • Meng J, Doyle MP. Emerging and evolving microbial foodborne pathogens. Bulletin de I'Institut Pasteur. 1998;96:151–164.
  • Molbak K, Baggesen DL, Aarestrup FM, Ebbesen JM, Engberg J, Frydendahl K, Gerner-Smidt P, Petersen AM, Wegener HC. An outbreak of multi-drug resistant, quinolone-resistant Salmonella enterica serotype typhimurium DT104. New England Journal of Medicine. 1999;341:1420–1425. [PubMed: 10547404]
  • Murray BE. Problems and dilemmas of antimicrobial resistance. Pharmacotherapy. 1992;12:86S–93S. [PubMed: 1480504]
  • Nakamura S, Yoshida H, Bogaski M, Nakamura M, Kojima T. Quinolone resistance mutations in DNA gyrase. In: Andoh T, Ikeda H, Oguro M, editors. Molecular Biology of DNA Topoisomerases and Its Application to Chemotherapy. London: CDC Press; 1993. pp. 135–143.
  • National Research Council; Committee on Drug Use in Food Animals; Panel on Animal Health, Food Safety, and Public Health; Board on Agriculture. The Use of Drugs in Food Animals: Benefits and Risks. Washington, DC: National Academy Press; 1999.
  • Nikolich MP, Hong G, Shoemaker NB, Salyers AA. Evidence for natural horizontal transfer of tetQ between bacteria that normally colonize humans and bacteria that normally colonize livestock. Applied and Environmental Microbiology. 1994;60:3255–3260. [PMC free article: PMC201796] [PubMed: 7944364]
  • Oosterom J. Epidemiological studies and proposed preventive measures in the fight against human salmonellosis. International Journal of Food Microbiology. 1991;12:41–51. [PubMed: 2018705]
  • Pantosti A, Del Grosso M, Tagliabue S, Macri A, Caprioli A. Decrease of vancomycin-resistant enterococci in poultry meat after avoparcin ban. Lancet. 1999;354:741–742. [PubMed: 10475190]
  • Pavia AT, Shipman LD, Wells JG, Puhr ND, Smith JD, McKinley TW, Tauxe RV. Epidemiologic evidence that prior antimicrobial exposure decreases resistance to infection by antimicrobial-sensitive Salmonella. Journal of Infectious Diseases. 1990;161:255–260. [PubMed: 2299207]
  • Rende-Fournier R, Leclercq R, Galimand M, Duval J, Courvalin P. Identification of the satA gene encoding a streptogramin A acetyltransferase in Enterococcus faecium BM4145. Antimicrobial Agents and Chemotherapy. 1993;37:2119–2125. [PMC free article: PMC192238] [PubMed: 8257133]
  • Riley LW, Cohen ML, Seals JE, Blaser MJ, Birkness KA, Hargrett NT, Martin SM, Feldman RA. Importance of host factors in human salmonellosis caused by multiresistant strains of Salmonella. Journal of Infectious Diseases. 1984;149:878–883. [PubMed: 6376655]
  • Ryan C, et al. Abstract. Abstracts of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy; Minneapolis. September 29–October 2, 1985.1985.
  • Ryan CA, Nickels MK, Hargrett-Bean NT, Potter ME, Endo T, Mayer L, Langkop CW, Gibson C, McDonald RC, Kenney RT, et al. Massive outbreak of antimicrobial-resistant salmonellosis traced to pasteurized milk. Journal of the American Medical Association. 1987;258:3269–3274. [PubMed: 3316720]
  • Shoemaker NB, Wang G, Salyers AA. Evidence for natural transfer of a tetracycline resistance gene between bacteria from the human colon and bacteria from the bovine rumen. Applied and Environmental Microbiology. 1992;58:1313–1320. [PMC free article: PMC195592] [PubMed: 1599250]
  • Smith KE, Besser JM, Hedberg CW, Leano FT, Bender JB, Wicklund JH, Johnson BP, Moore KA, Osterholm MT. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992–1998. New England Journal of Medicine. 1999;340:1525–1532. [PubMed: 10332013]
  • Sorensen TL, Wegener HC, Frimodt-Moller N. Resistant bacteria in retail meats and antimicrobial use in animals. New England Journal of Medicine. 2002;346:777–779. [Letter] [PubMed: 11882737]
  • Spika JS, Waterman SH, Hoo GW, St Louis ME, Pacer RE, James SM, Bissett ML, Mayer LW, Chiu JY, Hall B, et al. Chloramphenicol-resistant Salmonella Newport traced through hamburger to dairy farms. New England Journal of Medicine. 1987;316:565–570. [PubMed: 3807951]
  • Tauxe R. Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations. In: Nanchamkin I, Blaser MJ, Tompkins LS, editors. Campylobacter jejuni: Current Status and Future Trends. Washington, DC: American Society for Microbiology Press; 1992. pp. 9–19.
  • Tauxe RV, Cavanagh TR, Cohen ML. Interspecies gene transfer in vivo producing an outbreak of multiply resistant shigellosis. Journal of Infectious Diseases. 1989;160:1067–1070. [PubMed: 2685126]
  • USDA (United States Department of Agriculture). Nationwide Broiler Chicken Microbiological Baseline Data Collection Program, July 1994–June 1995. 1996. [Online]. Available: http://www​.fsis.usda​.gov/OPHS/baseline/contents.htm.
  • U.S. Government. Interagency Task Force on Antimicrobial Resistance. A Public Health Action Plan to Combat Antimicrobial Resistance. 2001. [Online]. Available: http://www​​/actionplan.
  • van den Bogaard AE, Stobberingh EE. Antibiotic usage in animals: impact on bacterial resistance and public health. Drugs. 1999;58:589–607. [PubMed: 10551432]
  • van den Bogaard AE, Bruinsma N, Stobberingh EE. The effect of banning avoparcin on VRE carriage in the Netherlands. Journal of Antimicrobial Chemotherapy. 2000;46:146–147. [PubMed: 10882707]
  • van den Bogaard AE, London N, Stobberingh EE. Antimicrobial resistance in pig faecal samples from The Netherlands (five abattoirs) and Sweden. Journal of Antimicrobial Chemotherapy. 2000;45:663–671. [PubMed: 10797090]
  • Wegener HC, Aarestrup FM, Jensen LB, Hammerum AM, Bager F. Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe. Emerging Infectious Diseases. 1999;5:329–335. [PMC free article: PMC2640785] [PubMed: 10341169]
  • WHO (World Health Organization). The Medical Impact of the Use of Antimicrobials in Food Animals: Report and Proceedings of a WHO Meeting; Berlin. October 13–17, 1997; Geneva: WHO; 1997.
  • WHO. Containing Antimicrobial Resistance: Review of the Literature and Report of a WHO Workshop on the Development of a Global Strategy for the Containment of Antimicrobial Resistance; Geneva. February 4–5, 1999; Geneva: WHO; 1999.
  • WHO. WHO Global Principles for the Containment of Antimicrobial Resistance in Animals Intended for Food: Report of a WHO Consultation; Geneva, Switzerland. June 5-9, 2000; Geneva: WHO; 2000.
  • Wierup M. Preventive methods replace antibiotic growth promoters: ten years experience from Sweden. APUA Newsletter. 1998;16:1–4.
  • Winokur PL, Brueggemann A, DeSalvo DL, Hoffmann L, Apley MD, Uhlenhopp EK, Pfaller MA, Doern GV. Animal and human multidrug-resistant, cephalosporin-resistant Salmonella isolates expressing a plasmid-mediated CMY-2 AmpC beta-lactamase. Antimicrobial Agents and Chemotherapy. 2000;44:2777–2783. [PMC free article: PMC90151] [PubMed: 10991860]
  • Winokur PL, Vonstein DL, Hoffman LJ, Uhlenhopp EK, Doern GV. Evidence for transfer of CMY-2 AmpC β-lactamase plasmids between Escherichia coli and Salmonella isolates from food animals and humans. Antimicrobial Agents and Chemotherapy. 2001;45:2716–2722. [PMC free article: PMC90722] [PubMed: 11557460]
  • Witte W. Medical consequences of antibiotic use in agriculture. Science. 1998;279:996–997. [PubMed: 9490487]
Copyright © 2003, National Academy of Sciences.
Bookshelf ID: NBK97132


  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (9.0M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...